CommercialCoverageMedium impact
Bioengineered Tissue Products for Wound Treatment and Surgical Interventions 7.01.35
Excellus BlueCross BlueShield·Wound Care, Dermatology, Plastic Surgery +2 more·Skin (Dermatology)
Effective date
Jul 17, 2025
We identified it
Jun 20, 2026
Summary
Excellus BlueCross BlueShield updated their policy for bioengineered tissue products used in wound treatment and surgical procedures, effective July 17, 2025. The policy establishes specific coverage criteria for various tissue products including diabetic foot ulcers, venous ulcers, breast reconstruction, burns, and other surgical applications with detailed medical necessity requirements.
Action Required
By July 17, 2025: Review and update prior authorization processes for bioengineered tissue products to ensure compliance with new medical necessity criteria. Billing team must verify coverage requirements for specific products (AlloPatch, Apligraf, Dermagraft, etc.) and ensure documentation meets detailed criteria including ABI requirements, wound characteristics, and contraindications. Update encounter forms to capture required elements like HbA1C levels for diabetic ulcers and adequate debridement documentation.